[{"bbox": [144, 193, 1556, 260], "category": "Text", "text": "Pursuant to a resolution passed by the Board dated September 29, 2025, our Company has approved the utilisation of the Net Proceeds for the Objects and the schedule of deployment and implementation, as set out below."}, {"bbox": [144, 289, 983, 324], "category": "Section-header", "text": "## Proposed schedule of implementation and deployment of Net Proceeds"}, {"bbox": [144, 354, 1556, 419], "category": "Text", "text": "We propose to utilise and deploy the Net Proceeds towards the Objects in accordance with the estimated schedule of implementation and deployment of funds set forth in the table below:"}, {"bbox": [1432, 417, 1554, 442], "category": "Text", "text": "(in ₹ million)"}, {"bbox": [144, 440, 1554, 909], "category": "Table", "text": "<table><thead><tr><th rowspan=\"2\">Particulars</th><th rowspan=\"2\">Total estimated costs</th><th rowspan=\"2\">Estimated amount proposed to be financed from Net Proceeds<sup>(2)</sup></th><th colspan=\"2\">Estimated utilisation of Net Proceeds</th></tr><tr><th>Financial year ended March 31, 2026</th><th>Financial year ended March 31, 2027</th></tr></thead><tbody><tr><td>Repayment/prepayment, in full or part, of all or certain outstanding borrowings availed by our Company</td><td>3,500.00</td><td>3,500.00</td><td>-</td><td>3,500.00</td></tr><tr><td>Funding of capital expenditure requirements for expansion through purchase of plant, machineries and equipment by our Company</td><td>2,526.00<sup>(3)</sup></td><td>2,250.00</td><td>-</td><td>2,250.00</td></tr><tr><td>General corporate purposes<sup>(1)(2)</sup></td><td>[•]</td><td>[•]</td><td>[•]</td><td>[•]</td></tr><tr><td><strong>Total<sup>(2)</sup></strong></td><td>[•]</td><td>[•]</td><td>[•]</td><td>[•]</td></tr></tbody></table>"}, {"bbox": [144, 909, 1091, 935], "category": "Text", "text": "(1) The amount to be utilised for general corporate purposes shall not exceed 25% of the Gross Proceeds."}, {"bbox": [144, 935, 1183, 961], "category": "Text", "text": "(2) To be finalised upon determination of the Offer Price and updated in the Prospectus prior to filing with the RoC."}, {"bbox": [144, 961, 996, 987], "category": "Text", "text": "(3) The balance cost of ₹276.00 million will be funded from internal accruals by our Company."}, {"bbox": [144, 1012, 1556, 1270], "category": "Text", "text": "The above-stated fund requirements, deployment of the Net Proceeds and the intended use of the Net Proceeds as described in this Draft Red Herring Prospectus are based on our current business plan, management estimates, market conditions and other external commercial and technical factors. However, such fund requirements and deployment of Net Proceeds have not been appraised by any bank, financial institution or any other independent agency. For further details, see “Risk Factors – Our funding requirements and proposed deployment of the Net Proceeds of the Offer are based on management estimates and have not been appraised by a bank or a financial institution and if there are any delays or cost overruns, our business, cash flows, financial condition and results of operations may be adversely affected. Any variation in the utilization of the Net Proceeds would be subject to certain compliance requirements, including prior shareholders’ approval” on page 53."}, {"bbox": [144, 1299, 1556, 1525], "category": "Text", "text": "We may have to revise our funding requirements and deployment on account of a variety of factors such as our financial and market condition, our business and growth strategies, our ability to identify and implement inorganic growth initiatives (including investments and acquisitions), competitive landscape, general factors affecting our results of operations, financial condition and access to capital and other external factors such as changes in the business environment or regulatory climate and interest or exchange rate fluctuations, which may not be within the control of our management. This may entail rescheduling the proposed utilization of the Net Proceeds and changing the allocation of funds from its planned allocation at the discretion of our management, subject to compliance with applicable law."}, {"bbox": [144, 1555, 1556, 1908], "category": "Text", "text": "Further, the Board of our Company may decide to accelerate the estimated Objects ahead of the schedule specified above. However, in the event that estimated utilization out of the Net Proceeds in a scheduled Fiscal being not undertaken in its entirety, the remaining Net Proceeds shall be utilized in subsequent Fiscals, as may be decided by the Board of our Company, in accordance with applicable laws. Any such change in our plans may require rescheduling of our expenditure programs and increasing or decreasing expenditure for a particular object vis-à-vis the utilization of Net Proceeds. In case of any surplus amount after utilization of the Net Proceeds towards any of the aforementioned Objects, we may use such surplus amount towards other Objects as set out above, provided that the total amount to be utilized towards general corporate purposes does not exceed 25% of the Gross Proceeds in accordance with applicable law. Further, in case of a shortfall in meeting the aforementioned Objects, we may explore a range of alternate funding options including utilizing our internal accruals and / or availing future debt from lenders. Our Predecessor Statutory Auditors have provided no assurance or services related to any prospective financial information."}, {"bbox": [144, 1938, 352, 1969], "category": "Section-header", "text": "## Means of finance"}, {"bbox": [144, 2001, 1556, 2132], "category": "Text", "text": "The fund requirements for the Objects are proposed to be entirely funded from the Net Proceeds and internal accruals. Accordingly, we confirm that there are no requirements to make firm arrangements of finance through verifiable means towards at least 75% of the stated means of finance, excluding the amount to be raised through the Fresh Issue and existing internal accruals, under Regulation 7(1) of the SEBI ICDR Regulations."}, {"bbox": [830, 2152, 870, 2180], "category": "Page-footer", "text": "119"}]